News

While the antibodies declined slightly at 3 months, all participants showed elevated levels.

Further investigation has to be conducted before this method can be used in human patients.

Initial high hopes for third vaccine available to the public, in addition to Pfizer and Moderna’s versions, are tempered as further data is sought.

Group is first to demonstrate the activation of inflammasome in response to infection by SARS-CoV-2.

COVID-19 is a dynamic disease which evolves as it disrupts host programs and rewires modules.

The agency adds 2 options lowering the number of days to isolate.

The research has helped almost 100 patients so far at the Royal Albert Edward Infirmary.

The Advisory Committee on Immunization Practices (ACIP) met yesterday and decided that healthcare workers and residents in long-term care facilities will be prioritized as the first people eligible for the impending COVID-19 vaccines.

Can chemical compounds found in certain foods aid in the fight against COVID-19?

LabCorp, an early adopter with extensive geographic reach, will be the first lab offering the test in the United States.

The companies are ready to ship doses immediately.

Mady Hornig, MA, MD, discusses the mental and emotional aspects of dealing with a diagnosis and the evolution of how people are processing the virus many months later after it started.

A team at Columbia University's Mailman School of Public Health is partnering with a chronic fatigue syndrome (CFS) organization to study COVID-19 and CFS.

Recent study may have implications for social and public health policies

Olfactory dysfunction is a critical loss of information that is important for responding to our environment.

Researchers produce the first-ever electron microscopy images of intact coronavirus particles within olfactory mucosa.

A team at Columbia University's Mailman School of Public Health is looking at the long term of effects in some patients who are suffering from this phenomenon.

New study may help contribute to COVID-19 research.

Patients with pervasive conditions are found to be more at risk for a severe case of COVID-19.

Mady Hornig, MA, MD, shares her experiences of having lingering effects as part of a phenomenon where some people suffer from the virus over many months.

A look at the logistical questions which remain with the two leading candidates.

An early trial of fluvoxamine to treat mild coronavirus disease 2019 (COVID-19) showed promising results, suggesting the antidepressant may help ward off clinical deterioration in patients with mild symptoms.

Articles not undergoing peer review are reaching widespread dissemination during the pandemic. What are the implications?

Researchers find most common mutations appear to have been induced by the human immune system.

A study author at Keck Medicine of USC discusses an ongoing assessment of LY-CoV555 for preventing severe COVID-19, and the overall benefit of the drug class for pandemic mitigation.

The IDSA representative discusses advances made in recent years, and how foundational guidance could be set by the FDA with input from specialists.

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

OncoSec recently received an FDA IND clearance to begin a phase 1 trial.

Important finding shows convalescent plasma provides no significant benefit in severe COVID-19 cases.

Recent study shows COVID-19 survivors health improves with support of Home Health Care.